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Pharmaceutics
viz., HSV type 1 and type 2. HSV type 1 is the herpes virus 
that is usually responsible for cold sores of the mouth, the 
so‑called fever blisters. HSV type 2 is the one that most 
commonly causes genital herpes.[1] The infection causes 
painful sores on the genitals in both men and women. 
In addition, herpes sores provide a way for HIV to get 
past the body’s immune defenses and make it easier to 
get HIV infection. A recent study found that people with 
HSV had three times the risk of becoming infected with 
HIV as compared to people without HSV.[2] Currently, the 
treatments available for herpes simplex are conventional 
tablets and topical gel for application on outbreaks. The 
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ABSTRACT
Acyclovir is an antiviral drug used for the treatment of herpes simplex virus infections, with an oral bioavailability of 
only 10–20% [limiting absorption in gastrointestinal tract to duodenum and jejunum] and half‑life of about 3 h, and 
is soluble only at acidic pH (pKa 2.27). Mucoadhesive polymeric nanodrug delivery systems of acyclovir have been 
designed and optimized using 23 full factorial design. Poly (lactic‑co‑glycolic acid) (PLGA) (50:50) was used as the 
polymer along with polycarbophil (Noveon AA‑1) as the mucoadhesive polymer and pluronic F68 as the stabilizer. 
From the preliminary trials, the constraints for independent variables X1 (amount of PLGA), X2 (amount of pluronic 
F68) and X3 (amount of polycarbophil) have been fixed. The dependent variables that were selected for study were 
particle size (Y1), % drug entrapment (Y2) and % drug release in 12 h (Y3). The derived polynomial equations were 
verified by check point formulation. The application of factorial design gave a statistically systematic approach for 
the formulation and optimization of nanoparticles with the desired particle size, % drug release and high entrapment 
efficiency. Drug: Polymer ratio and concentration of stabilizer were found to influence the particle size and entrapment 
efficiency of acyclovir‑loaded PLGA nanoparticles. The release was found to follow Fickian as well as non‑Fickian 
diffusion mechanism with zero‑order drug release for all batches. In vitro intestinal mucoadhesion of nanoparticles 
increased with increasing concentration of polycarbophil. These preliminary results indicate that acyclovir‑loaded 
mucoadhesive PLGA nanoparticles could be effective in sustaining drug release for a prolonged period. 
Key words: 23 factorial design, acyclovir, mucoadhesive, nanoparticles, poly (lactic‑co‑glycolic acid)
Access this article online
Quick Response Code:
Website:  
www.jyoungpharm.in
DOI:  
10.4103/0975‑1483.90236Bhosale, et al.: Mucoadhesive nano drug delivery system of acyclovir
276   Journal of Young Pharmacists Vol 3 / No 4
drugs that are commonly used for herpes simplex are 
acyclovir, valaclovir and famciclovir.
Acyclovir, the first agent to be licensed for the treatment of 
HSV infections, is the most widely used drug for infections 
such as cutaneous herpes, genital herpes, chicken pox, 
and varicella zoster. Acyclovir is currently marketed as 
capsules (200 mg), tablets (200 mg, 400 mg and 800 mg) 
and topical ointment.[1] Oral acyclovir is mostly used as 
200 mg tablets, five times a day. In addition, long‑term 
administration of acyclovir (6 months or longer) is required 
in immunocompromised patients with relapsing herpes 
simplex infection.[2] The presently available conventional 
therapy is associated with a number of drawbacks such as 
highly variable absorption and low bioavailability (10–20%) 
after oral administration.[3] Furthermore, with increase in 
dose, there is decrease in bioavailability. Moreover, because 
the mean plasma half‑life of the drug is 2.5 h, five times 
a day administration is required. In order to make oral 
therapy of acyclovir more patient compliant, there is a 
need of using different approaches like matrix tablets, 
nanoparticles[4] and polymeric films.[5] 
The main problem with the therapeutic effectiveness of 
acyclovir is its absorption which is highly variable and dose 
dependent, thus reducing the bioavailability to 10–20%.[6] 
Acyclovir is soluble in acidic pH and is predominantly 
absorbed from upper gastrointestinal tract (GIT).[7] There 
are indications of its active absorption from the duodenum 
and jejunum regions of GIT.[8] 
The inherent shortcomings of conventional drug delivery 
and the potential of nanoparticles as drug delivery systems 
have offered tremendous scope for researchers in this 
field and there is a fast movement from concept to reality. 
Nanoparticles may be used for oral administration of 
gut‑labile drugs or those with low aqueous solubility.[9] 
These colloidal carriers have the ability to cross the 
mucosal barrier as such. In addition, they have the 
potential for enhancing drug bioavailability via particle 
uptake mechanisms. It was therefore decided to prepare 
nanoparticles of acyclovir so as to optimize its delivery and 
overcome its inherent drawbacks.
The concept of mucosal adhesives or mucoadhesives 
was introduced into the controlled drug delivery arena in 
the early 1980s.[10] Mucoadhesives are synthetic or natural 
polymers which interact with the mucus layer covering the 
mucosal epithelial surface and mucin molecules constituting 
a major part of the mucus. They localize the formulation 
at a particular region of the body, thereby improving 
bioavailability of the drugs with low bioavailability. The 
increased contact time and localization of the drug 
due to applying nanoparticles of acyclovir which are 
made mucoadhesive thus enhances its delivery. Possible 
added advantage of this approach would be increase 
in bioavailability as well as reduction in frequency of 
administration.
For the present investigation, mucoadhesive polymeric 
nanodrug delivery systems of acyclovir have been 
designed and optimized using 23 full factorial design. Poly 
(lactic‑co‑glycolic acid) (PLGA) (50:50) was used as the 
polymer along with polycarbophil (Noveon AA‑1) used 
as the mucoadhesive polymer and pluronic F68 was used 
as the stabilizer.
MATERIALS AND METHODS
Acyclovir was a gift sample from Ajanta Pharmaceutical 
Limited (Mumbai India); poly (D, L lactide‑co‑glycolide) 
(PLGA 50:50 and PLGA 85:15) were obtained as gift 
samples from Indena Ltd. (Rome, Italy); pluronic F68 and 
polycarbophil (Noveon AA‑1) were procured from Strides 
Arcolab, (Bangalore, India) as a gift; acetone and cellophane 
membrane were purchased from S. D. Fine Chem. Ltd. 
(Mumbai, India). All other reagents and chemicals used in 
this study were of analytical grade.
Methods
Mucoadhesive PLGA nanoparticles
Mucoadhesive PLGA nanoparticles were prepared by 
the solvent deposition method. Acyclovir was dissolved 
at 35–40°C in neutral water containing a hydrophilic 
surfactant at various concentrations. A mucoadhesive 
polymer, polycarbophil, was dispersed in this aqueous 
phase. Organic phase was prepared by solubilizing PLGA 
in acetone at various concentrations. The organic phase 
was poured into the aqueous solution drop wise, under 
stirring (RPM 5000) for 2 h, thus forming a milky colloidal 
suspension. The organic solvent was then evaporated by 
using a Rota evaporator. The resultant dispersion was dried 
using a freeze drying method.[11,12] 
Experimental design
The formulations were fabricated according to a 23 full 
factorial design, allowing the simultaneous evaluation 
of three formulation variables and their interaction. The 
experimental designs with corresponding formulations 
are outlined in Table 1. The dependent variables that 
were selected for study were: Particle size (Y1), % drug 
entrapment (Y2) and % drug release in 12 h (Y3).Bhosale, et al.: Mucoadhesive nano drug delivery system of acyclovir
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In vitro characterization of PLGA nanoparticles
Determination of  particle size
The particle size and size distribution of the acyclovir‑loaded 
mucoahesive PLGA (50:50) nanoparticles were 
characterized by laser light scattering using Particle size 
Analyzer (Malvern Mastersizer Hydro‑2000 SM, UK). The 
obscuration level was set between 7 and 11%, and distilled 
water was used as the medium.
Determination of encapsulation efficiency
The free drug was estimated by taking said quantity of 
formulation in a dialysis bag (cellophane membrane, 
molecular weight cutoff 10,000–12,000 Da; Hi‑Media, 
Mumbai, India) which was tied and placed into 100 ml 
water (pH=7) maintained at 37 ± 5°C on magnetic stirrer. 
At predetermined time intervals, 5 ml of the sample was 
withdrawn by means of a syringe. The volume withdrawn at 
each interval was replaced with the same quantity of fresh 
water (pH=7) maintained at 37 ± 5ºC. The samples were 
analyzed for free drug by measuring the absorbance at 252 nm 
using UV/Vis spectrophotometer (ShimadzuUV‑1700) 
after suitable dilution. The above‑described process of 
withdrawing sample and analysis was continued till a 
constant absorbance was obtained.[13] 
Encapsulated drug was estimated by taking residue 
formulation remaining behind in the dialysis membrane 
after the estimation of free drug content, as described above. 
Formulation in dialysis bag was added to acetone (10 ml) to 
dissolve PLGA and filtered. The residue remaining on filter 
paper was dissolved in 100 ml of water (pH=7) maintained 
at 37 ± 5ºC, and after removing the supernatant, the sample 
was analyzed for drug content by measuring the absorbance 
at 252 nm using UV/Vis spectrophotometer (Shimadzu 
UV‑1700) after suitable dilution. The percentage of drug 
entrapped and the percentage of free drug were calculated 
using the following equations:[14]
Amount of free drug present in  
100 mg of formulation
% Free drug = ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ × 100  (1)
Total amount of drug present  
in 100 mg of formulation
Amount of encapsulated  
drug  present in 100 mg  
of formulation % Drug entrapment = ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ × 100  (2)
Total amount of drug  
present in 100 mg  
of formulation 
Statistical analysis
The results from factorial design were evaluated using Sigma 
plot software (Systat Software Inc., Version 3.0, Richmond, 
CA software). Step‑wise backward linear regression analysis 
was used to develop polynomial equations for dependent 
variables[15,16] such as particle size (Y1) % drug entrapment 
(Y2) and % drug release in 12 h (Y3): 
Y = B0 + B1X1 + B2X2 + B3X3 + B11X1
2 + B22X2
2 + 
B33X3
2 + B12X1X2 + B13X1X3 + B23X2X3 + B123X1X2X3 
  (3),
where Y is a dependent variable, B0 the arithmetic mean 
response of eight batches, and B1, B2, and B3 are estimated 
coefficients for factors X1, X2 and X3, respectively. The 
main effects (X1, X2 and X3) represent average result of 
changing one factor at a time from its low and high values. 
The interaction terms (X1X2), (X1X3), (X2X3) show how the 
response changes when three factors are simultaneously 
changed. The polynomial term (X1X2X3) is included to 
investigate non‑linearity. The validity of the developed 
polynomial equations was verified by preparing check point 
formulation (C).
Drug release study
A quantity of selected factorial formulations equivalent to 
25 mg of the drug was taken in the dialysis bag (cellophane 
membrane, molecular weight cutoff 10,000–12,000 Da; 
Hi‑Media). The dialysis bag was then suspended in a flask 
containing 100 ml of 0.1 N HCl on a magnetic stirrer at 
37 ± 0.5ºC at 100 rpm. Required quantity (5 ml) of the 
medium was withdrawn at specific time periods (1, 2, 3, 4, 
6, 8, 10, 12, 24, 32 h) and the same volume of dissolution 
Table 1: Experimental design and parameters for 23 full 
factorial design batches
Batch 
code
Variable level in 
coded form
Particle 
size 
(nm)
% Drug 
entrapment
% Drug 
release 
in 12 h
Average % 
intestinal 
retention X3
§ X1* X2
#
MF1
MF2
MF3
MF4
MF5
MF6
MF7
MF8
C
+1
−1
+1
−1
+1
−1
+1
−1
−0.5
+1
+1−1
−1
+1
+1
−1
−1
−0.5
+1
+1
+1
+1
−1
−1
−1
−1
−0.5
1580
1210
1630
1420
870
740
914
810
1107
93.7
89.9
94.1
88.12
84.12
80.16
86.26
80.09
80.59
54.04
59.52
53.32
57.35
65.33
71.14
63.72
67.02
64.43
49.3
62.1
45.7
55.6
56.2
67.3
52.5
59.7
‑
*For PLGA (50:50) (X1) transformed levels in polymer weight are: −1 = 175 mg; 
+1 = 250 mg; −0.5 = 193.75 mg. #For surfactant (pluronic F68) (X2) transformed 
levels in % are: −1 = 0.20%; +1 = 0.30%; −0.5 = 22.5%. §For mucoadhesive 
polymer (polycarbophil) (X3) transformed levels in % are: −1 = 0.10%; +1 = 0.15%; 
−0.5 = 11.25%Bhosale, et al.: Mucoadhesive nano drug delivery system of acyclovir
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medium was replaced in the flask to maintain a constant 
volume. The withdrawn samples were filtered and then 5 ml 
filtrate was made up to volume with 100 ml of 0.1 N HCl. 
The samples were analyzed for drug release by measuring the 
absorbance at 252 nm using UV/Vis spectrophotometer.[16]
In vitro evaluation of intestinal mucoadhesion of 
nanoparticles
The Institutional Animals Ethical Committee (IAEC) of 
Al‑Ameen College of Pharmacy, Bangalore, approved 
the protocol for the study. Male Sprague Dawley rats 
weighing 200–250 g were fasted overnight before the 
experiments, but allowed free access to water. A part of 
intestine (duodenum and jejunum) was excised under 
anesthesia and perfused with physiological saline to 
remove the contents of stomach. The cleaned portion 
was used immediately after preparation. A 50 mg 
quantity of mucoadhesive nanoparticle sample that 
was suspended in phosphate buffer (pH 6.8) was filled 
into the cleaned intestine, ligated and then incubated 
in physiological saline at 37°C for 30 min. The liquid 
content of separated portion of intestine was then 
removed by injecting the air and the same was perfused 
with phosphate (pH 6.8) for 2 h, at a flow rate of 1 ml/
min. The intestine was cut open and the nanoparticles 
that remained in it were recovered with phosphate 
buffer (pH 6.8). The final volume of washing solution 
was mixed with 10 ml of acetone solution and kept 
for 2 h for complete digestion of nanoparticles. After 
filtration through a 0.45‑mm filter paper, absorbance 
was determined spectrophotometrically at 252 nm 
(acyclovir) and gastric mucoadhesion was determined 
as the % of nanoparticles remaining in intestine after 
perfusion.[17]
Drug–polymer interaction studies
Differential scanning calorimetry (DSC) is one of the 
most powerful analytical techniques, which offers the 
possibility of detecting chemical interaction. Acyclovir 
(pure drug), PLGA, and physical mixtures of drug and 
polymer at different ratios (1:1, 1:1.5, 1:2, 1:2.5) were kept at 
40 ± 2°C/75 ± 5% relative humidity (RH). Samples at 0.1, 
2, 3 and 6 months were withdrawn and sent for DSC analysis. 
Also, drug–polymer interaction for selected formulation of 
coated and uncoated nanoparticles was evaluated by DSC 
(Perkin‑Elmer DSC 7, USA). Thermograms of acyclovir, 
polymer (PLGA), and mucoadhesive nanoparticles were 
obtained with 5°C/min of heating rate at a temperature 
between 50°C and 280°C.
SEM photomicrographs
The morphology of coated and uncoated nanoparticles 
was examined by scanning electron microscopy (SEM, 
JSM‑5310LV scanning microscope Tokyo, Japan). 
The nanoparticles were mounted on metal stubs using 
double‑sided tape and coated with a 150 Å layer of gold 
under vacuum. Stubs were visualized under scanning 
electron microscope.
RESULTS AND DISCUSSION
Mucoadhesive drug delivery system prolongs the residence 
time of the dosage form at the site of application or 
absorption and facilitates an intimate contact of the 
dosage form with the underlying absorption surface, and 
thus contributes to improved and/or better therapeutic 
performance of the drug. Acyclovir is predominantly 
absorbed from upper GIT and specifically there are 
indications for its active absorption from the duodenum 
and jejunum regions of GIT. In commercially available 
dosage forms, the amount of drug absorbed is very low 
(10–20%) due to short residence time of the dosage 
forms at the absorption site. As a result, most of the drug 
is excreted in the feces (50–60%) in unabsorbed form.[18] 
Hence, it can be envisaged that increasing the residence 
time at the absorption site can enhance the absorption 
and bioavailability of acyclovir. Therefore, it was decided 
to formulate and develop mucoadhesive nanoparticles of 
acyclovir and investigate its potential of optimizing delivery 
of the drug as compared to the presently used dosage 
forms which suffer from several drawbacks as mentioned.
Appropriate selection of the polymeric matrix is 
necessary in order to develop a successful nanoparticulate 
delivery system. Biodegradable polymers have received 
much attention in recent years.[19] PLGA has been most 
extensively used because of its biocompatibility and 
biodegradability, with the degradation products formed 
at a slow rate, thus not affecting the normal cell function. 
PLGA degrades in vivo to lactic and glycolic acids, which are 
subsequently eliminated as carbon dioxide and water via the 
Krebs cycle.[20] The release of drug from the nanoparticles 
depends on polymer degradation, which is governed by 
the nature of copolymer composition and its molecular 
weight. For this study, we used PLGA 50:50, which is 
known to hydrolyze at a faster rate than those containing 
a higher proportion of polylactic acid.[21] Noveon AA‑1 
polycarbophil, USP is a high molecular weight acrylic 
acid polymer cross‑linked with divinyl glycol. It provides 
excellent bioadhesive properties and has been used 
extensively to enhance the delivery of active ingredients Bhosale, et al.: Mucoadhesive nano drug delivery system of acyclovir
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to various mucus membranes. Acetone is used as a solvent 
for the preparation of PLGA nanoparticles due to its water 
miscible and comparatively non‑toxic nature.[20]
All microsphere formulations were spherical in shape 
and possessed smooth surface as visualized under SEM 
[Figure 1]. Out of all mucoadhesive formulations developed 
according to the factorial design and the above‑described 
method, MF2, MF5, MF6 and MF8 were found to be free 
flowing, i.e. non‑sticky, but formulations MF1, MF3, MF4 
and MF7 were found to be sticky. All formulations were 
white and powdery in appearance.
The particle size affects the biopharmaceutical, 
physicochemical and drug release properties of the 
nanoparticles. A graphical representation of the particle size 
of mucoadhesive nanoparticles obtained is given in Figure 1. 
Particle size is an important parameter because it has a direct 
relevance to the stability of the formulation. Larger particles 
tend to aggregate to a greater extent compared to smaller 
particles, thereby resulting in sedimentation.[16] The amount 
of stabilizer used also has an effect on the properties of 
nanoparticles. If the concentration of stabilizer is too low, 
aggregation of the polymer will take place, whereas if too 
much stabilizer is used, drug incorporation could be reduced 
as a result of the interaction between the drug and stabilizer.[1]
The effect of the concentration of the polymers tested 
is negative or positive. A positive effect would imply 
that increasing the concentration causes the emulsion to 
have larger droplets, thereby leading to larger particles. 
A negative effect means that increasing the concentration 
causes the emulsion to be more stable, thereby leading to 
smaller particles.[17]
From Figures 2 and 3 and Table 1, it is seen that as drug: 
polymer (acyclovir: PLGA or acyclovir: polycarbophil) 
ratios increase from 1:0.875 to 1:1.25 (for PLGA) and from 
1:0.6 to 1:0.9 (for polycarbophil), particle size and drug 
entrapment efficiency increase significantly. It also reveals 
that concentration of the stabilizer has a significant effect 
on particle size, but it has insignificant or negligible effect 
on drug entrapment efficiency of nanoparticles.
This can be explained by observing particle size and % drug 
entrapment of mucoadhesive factorial formulations MF1 
and MF2, and MF7 and MF8, where the drug: Polymer 
(PLGA) ratio increased from 1:0.875 to 1:1.25, with a 
constant concentration of stabilizer (pluronic F68), i.e. 
0.3% for MF1 and MF2 and 0.2% for MF7 and MF8. The 
drug entrapment efficiency increased from 89.9 to 93.7% 
Figure 2: Comparison of particle size of mucoadhesive factorial 
formulations and check point formulation 
Figure 3: Comparison of % drug entrapment and % drug release in 
12 h of factorial and check point formulations Figure 1: SEM of PLGA nanoparticles
a
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and from 80.09 to 86.26%, respectively; also, the particle 
size increased from 1210 to 1580 nm and from 810 to 
914 nm, respectively.
In the same way, it can be explained with respect to 
mucoadhesive factorial formulations MF1 and MF5, and 
MF4 and MF8, where the drug: polymer ratio increased 
from 1:0.6 to 1:0.9, with a constant concentration of the 
stabilizer (pluronic F68), i.e. 0.3% for MF1 and MF5 and 
0.2% for MF4 and MF8. The drug entrapment efficiency 
increased from 84.12 to 93.7% and from 80.09 to 88.12%, 
respectively; also, the particle size increased from 870 to 
1580 nm and from 810 to 1420 nm, respectively.
But it has been observed for mucoadhesive factorial 
formulations MF1 and MF3, and MF6 and MF8, where 
the stabilizer concentration increased from 0.2 to 0.3%, 
with a constant drug: polymer ratio, i.e. 1:1.25 for MF1 and 
MF3 and 1:0.875 for MF6 and MF8, that the particle size 
decreased from 163 to 1580 nm and from 810 to740 nm, 
respectively; but at the same time, there was an insignificant 
or a negligible change in the drug entrapment efficiency as 
it changed from 94.1 to 93.7% and from 80.09 to 80.16%, 
respectively. Thus, it can be concluded that polymer and 
surfactant concentration has a significant effect on the 
particle size. However, there is insignificant or negligible 
effect of surfactant concentration on drug entrapment 
efficiency.
Drug release from nanoparticles and subsequent 
biodegradation are important for developing successful 
formulations. The release rate of nanoparticles depends 
upon i) desorption of the surface‑bound/adsorbed drug; 
ii) diffusion through the nanoparticle matrix; iii) diffusion 
(in case of nanocapsules) through the polymer wall; 
iv) nanoparticle matrix erosion; and v) a combined erosion/
diffusion process. Thus, diffusion and biodegradation 
govern the process of drug release.[22]
It is generally anticipated for a bulk eroding polymer such 
as 50:50 PLGA to give an initial burst release followed 
by a controlled release, in contrast to the release pattern 
observed in other controlled release systems, for example, 
sustain release tablets, pellets and beads. In cases where 
there is an initial burst effect, the high initial release may 
be attributed to the presence of crystals of free and weakly 
bound drug on the surface of the particulate carriers.[23]
The mechanism of drug release from nanoparticles is 
determined by different physical–chemical phenomena. 
The exponent n has been proposed as indicative of the 
release mechanism. In this context, n=0.43 indicates 
Fickian release, n=0.85 indicates a purely relaxation (case II) 
and >0.85 indicates super case II controlled delivery. 
Intermediate values 0.43<n<0.85 indicate an anomalous 
behavior (non‑Fickian kinetics) corresponding to coupled 
diffusion/polymer relaxation.[24] 
The average percentage release was fitted into different 
release models: Zero‑order, first‑order and Higuchi’s square 
root plot. The models giving a correlation coefficient close 
to unity were taken as the order of release. In vitro drug 
release data of all factorial formulations were subjected to 
goodness of fit test by linear regression analysis according 
to zero‑order and first‑order kinetic equations, Higuchi’s 
and Korsmeyer–Peppas models to ascertain the mechanism 
of drug release. From the various parameters determined 
for drug release from nanoparticles based on Peppas model, 
Higuchi model and diffusion profile, it is evident that values 
of “r2” for Higuchi plots of all mucoadhesive factorial 
formulations are close to unity, i.e. linear (drug release 
by diffusion). Diffusion exponent values “n” of Peppas 
equation for MF1, MF2 and MF3 are 0.6446, 0.5074 and 
0.6435, respectively, and show non‑Fickian diffusion, and 
for MF4, MF5, MF6, MF7 and MF8 are 0.4286, 0.3858, 
0.3225, 0.3942 and 0.3311, respectively, showing Fickian 
diffusion. Table 2 and Figure 4, shows almost zero‑order 
drug release for all factorial formulations as correlation 
coefficient of zero order drug release is close unity than 
first order drug release correlation coefficient. It can be 
concluded that the different drug release rates may be 
attributed to different sizes of the nanoparticles. It is 
expected that as the particle size of PLGA nanoparticle is 
smaller, its surface area will be more and the drug release 
is faster.[17]
From the data of experimental design and parameters 
[Table 1] for mucoadhesive factorial formulations F1–
F8, polynomial equations for three dependent variables 
(particle size, % drug entrapment and % drug release in 
12 h) have been derived using Sigma plot software (Systat 
Software Inc., Version 3.0, Richmond, CA software.)
Table 2: Various pharmacokinetic parameters 
determined for drug release
Formulation Correlation 
coefficient 
(zero order)
Correlation 
coefficient 
(first order)
Kinetic/
diffusion 
exponent“n”
Correlation 
coefficient 
(Higuchi model)
MF1
MF2
MF3
MF4
MF5
MF6
MF7
MF8
0.989
0.983
0.975
0.973
0.961
0.936
0.956
0.937
0.0091
0.0040
0.0150
0.0110
0.0020
0.0040
0.0060
0.0010
0.6446
0.5074
0.6435
0.4286
0.3858
0.3225
0.3942
0.3311
0.9897
0.9832
0.9759
0.973
0.9618
0.936
0.956
0.937Bhosale, et al.: Mucoadhesive nano drug delivery system of acyclovir
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The equation derived for particle size is:
Y1= 1136.7+11.75 X1–36.75 X2 +303.25 X3  
+13.25 X1 X2‑8.25X 2X3+53.25X 1X3   (4)
The equation derived for % drug entrapment is:
Y2= 87.0563+2.4887 X1–0.0862 X2  
+4.3987X3 ‑0.5487X1X2+0.4313X 2X3‑0.0438X 1X3  (5)
The equation derived for % drug release in 12 h is:
Y 3=  63.07‑2.2175  X1+1.1725  X2‑5.2750X3 
‑0.45X1X2‑0.2925X 2X3‑0.0075X 1X3   (6)
In Equation (4), negative sign for coefficient of X2 indicates 
that the particle size of nanoparticles increases when the 
concentration of pluronic F 68 is decreased and positive 
sign for coefficients of X1 and X3 indicates positive effect 
of polymer concentrations (PLGA and polycarbophil) on 
the particle size.
In Equation (5), positive sign for coefficients of X1 and 
X3 indicates that the % drug entrapment increases when 
the concentrations of PLGA and polycarbophil increase 
and negative sign for coefficient of X2 indicates that % 
drug entrapment of nanoparticles increases when the 
concentration of pluronic F68 decreases. Also, the value of 
coefficient for X2 (−0.0862) shows insignificant or negligible 
effect of an independent variable on a dependent variable.
In Equation (6), negative sign for coefficient of X1 and X3 
indicates that the % drug release in 12 h increases when the 
concentrations of PLGA and polycarbophil decrease and 
positive sign for coefficient of X2 indicates positive effect 
of pluronic F68 concentration on % drug release in 12 h.
Validity of the above equations was verified by designing 
check point formulation (C). The particle size, % drug 
entrapment and % drug release in 12 h from the equations 
derived and those observed from experimental results are 
summarized in Table 3. The closeness of predicted and 
observed values for particle size and % drug entrapment 
indicates validity of derived equations for dependent 
variables.
Graphical presentation of the data can help to show 
the relationship between response and independent 
variables. Graphs gave information similar to that of the 
mathematical equations obtained from statistical analysis. 
The response surface graphs of particle size and % drug 
entrapment, % drug release in 12 h are presented in 
Figures 5‑7 respectively.
The response surface plots and contour plots illustrate 
that as the concentration of polymers (PLGA and 
polycarbophil) increases, the value of dependent variable, 
i.e. particle size, increases; also, as the concentration of 
stabilizer (pluronic F68) increases, the value of dependent 
variable, i.e. particle size, decreases.
Similarly, the response surface plots and contour 
plots for % drug entrapment shows positive effects 
of independent variable, i.e. polymer concentrations 
(PLGA and polycarbophil) and negative effect of other 
independent variable, i.e. concentration of stabilizer 
(pluronic F68).
But in contrast to this illustration, the response surface 
plot and contour plot for % drug release in 12 h shows 
negative effect of independent variable, i.e. polymer 
concentrations (PLGA and polycarbophil) and positive 
effect of independent variable, i.e. concentration of 
stabilizer (pluronic F68) on % drug release in 12 h. 
Mucoadhesion involves different kinds of interaction 
forces between mucoadhesive materials and mucus surface, 
such as electrostatic attraction, hydrogen bonding, Van 
der Waals forces and mechanical interpenetration and 
entanglement.[19]
Spectrophotometric method (λmax 252 nm) used to measure 
in vitro mucoadhesive capacity of developed formulations 
shows the % intestinal retention of mucoadhesive 
nanoparticles in the rat intestinal mucosa. The adhesion 
properties of nanoparticles increased with increasing 
concentration of mucoadhesive polymer (polycarbophil); 
Table 3: Parameters of check point formulation
Formulation Predicted values Observed values
Particle 
size 
(nm)
% Drug 
entrapment
% 
Drug 
release 
in 12 h
Particle 
size 
(nm)
% Drug 
entrapment
% 
Drug 
release 
in 12 h
C 1012 83.61 66.03 1107 80.59 64.43
Figure 4: Average % drug release of mucoadhesive factorial formulationsBhosale, et al.: Mucoadhesive nano drug delivery system of acyclovir
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Figure 7: Response surface plots of effects of factorial variables on 
% drug release in 12 h Figure 8: DSC thermograms
among the various concentrations of polycarbophil, better 
mucoadhesion was observed for MF2 and MF6 formulations 
as 67.3% and 62.1%, respectively [Table 1].
DSC gives information regarding the physical properties 
like crystalline or amorphous nature of the samples. The 
DSC thermogram of acyclovir [Figure 8a] shows an 
exothermic peak at 267.03 corresponding to its melting 
temperature, which was not detected in the thermograms for 
acyclovir‑loaded coated and uncoated nanoparticles of PLGA 
50:50 [Figures 8b and c]. It has been shown by a couple of 
authors that when the drug does not show its exothermic 
peak in the formed nanoparticles, it is said to be in the 
amorphous state.[25] Hence, it could be concluded that in both 
the prepared PLGA nanoparticles (coated and uncoated), the 
drug was present in the amorphous phase and may have been 
homogeneously dispersed in the PLGA matrix.
CONCLUSION
PLGA nanoparticles were prepared by the solvent 
deposition method and were characterized as 
“mucoadhesive” by coating with mucoadhesive polymer, 
polyacrylic acid (polycarbophil). The application of 
factorial design gave a statistically systematic approach 
for the formulation of nanoparticles with the desired 
particle size, high entrapment efficiency and sustained 
drug release. Drug: polymer ratio and concentration 
of surfactant were found to influence the particle 
size and % drug release of acyclovir‑loaded PLGA 
mucoadhesive nanoparticles. In vitro drug release study of 
all formulations (MF1–MF8) showed 57.71–78.31% drug 
release in 32 h. The release was found to follow Fickian 
as well as non‑Fickian diffusion mechanism with almost 
zero‑order drug release for all batches. In vitro intestinal 
mucoadhesion of nanoparticles showed that the adhesion 
properties of nanoparticles increased with increasing 
concentration of mucoadhesive polymer (polycarbophil). 
These preliminary results indicate that acyclovir‑loaded 
mucoadhesive PLGA nanoparticles could be effective in 
sustaining drug release for a prolonged period. Further 
studies are needed to confirm its performance in vivo.
Thus, the above investigation involves extensive and 
in‑depth holistic studies of mucoadhesive and site‑specific 
Figure 5: Response surface plots of effects of factorial variables on 
% drug entrapment
Figure 6: Response surface plots of effects of factorial variables on 
particle sizeBhosale, et al.: Mucoadhesive nano drug delivery system of acyclovir
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nanoparticles tailored to achieve controlled release of 
predetermined quantities of the drug, resulting in not 
only optimizing drug delivery but also development of 
a platform technology which has extensive patenting 
potential and can be useful for so many other such drugs.
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